{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:29:16Z","timestamp":1792045756680,"version":"4.4.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,26]],"date-time":"2016-12-26T00:00:00Z","timestamp":1482710400000},"content-version":"vor","delay-in-days":360,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mtm.2016.30","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T16:26:25Z","timestamp":1461774385000},"page":"16030","source":"Crossref","is-referenced-by-count":98,"special_numbering":"C","title":["Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens"],"prefix":"10.1016","volume":"3","author":[{"given":"Sam","family":"Afkhami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl. 1","key":"10.1038\/mtm.2016.30_bib1","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1002\/jgm.496","article-title":"Adenoviral vectors for gene transfer and therapy","volume":"6","author":"Volpers","year":"2004","journal-title":"J Gene Med"},{"key":"10.1038\/mtm.2016.30_bib2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.30_bib3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.30_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/hum.2013.235","article-title":"Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field","volume":"25","author":"Majhen","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nbt.1769","article-title":"Gene therapy finds its niche","volume":"29","author":"Sheridan","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtm.2016.30_bib6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mtm.2016.30_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/16000617.00002515","article-title":"Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments","volume":"24","author":"Lai","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1038\/mtm.2016.30_bib8","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1016\/j.vaccine.2011.06.071","article-title":"Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8\u03b1+ dendritic cell subset","volume":"29","author":"Suleman","year":"2011","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.virol.2010.10.020","article-title":"Computational analysis and identification of an emergent human adenovirus pathogen implicated in a respiratory fatality","volume":"409","author":"Robinson","year":"2011","journal-title":"Virology"},{"key":"10.1038\/mtm.2016.30_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2004.15.1022","article-title":"Biology of adenovirus and its use as a vector for gene therapy","volume":"15","author":"McConnell","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib11","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.30_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.gt.3302675","article-title":"Chimpanzee-origin adenovirus vectors as vaccine carriers","volume":"13","author":"Tatsis","year":"2006","journal-title":"Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1038\/mtm.2016.30_bib14","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2016.30_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: from virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1038\/mtm.2016.30_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"Biotechniques"},{"key":"10.1038\/mtm.2016.30_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/10430340360535797","article-title":"Optimization of the generation and propagation of gutless adenoviral vectors","volume":"14","author":"Sakhuja","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF02789331","article-title":"Methods for construction of adenovirus vectors","volume":"3","author":"Graham","year":"1995","journal-title":"Mol Biotechnol"},{"key":"10.1038\/mtm.2016.30_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1385\/MB:18:1:63","article-title":"Construction of adenoviral vectors","volume":"18","author":"Davis","year":"2001","journal-title":"Mol Biotechnol"},{"key":"10.1038\/mtm.2016.30_bib20","doi-asserted-by":"crossref","first-page":"e5059","DOI":"10.1371\/journal.pone.0005059","article-title":"Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines","volume":"4","author":"Weaver","year":"2009","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib21","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1038\/mtna.2013.55","article-title":"Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors","volume":"2","author":"Cao","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mtm.2016.30_bib22","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1128\/JVI.78.11.5966-5972.2004","article-title":"Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo","volume":"78","author":"Muruve","year":"2004","journal-title":"J Virol"},{"key":"10.1038\/mtm.2016.30_bib23","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","article-title":"Production of first generation adenovirus vectors: a review","volume":"7","author":"Danthinne","year":"2000","journal-title":"Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib24","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/v2081681","article-title":"Adenoviral producer cells","volume":"2","author":"Kovesdi","year":"2010","journal-title":"Viruses"},{"key":"10.1038\/mtm.2016.30_bib25","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1099\/vir.0.81956-0","article-title":"Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells","volume":"87","author":"Havenga","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1038\/mtm.2016.30_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1089\/10430340252939023","article-title":"A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles","volume":"13","author":"Murakami","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib27","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/sj.gt.3302088","article-title":"High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells","volume":"10","author":"Gao","year":"2003","journal-title":"Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib28","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1128\/JVI.69.6.3920-3923.1995","article-title":"Efficient selection of recombinant adenoviruses by vectors that express beta-galactosidase","volume":"69","author":"Schaack","year":"1995","journal-title":"J Virol"},{"key":"10.1038\/mtm.2016.30_bib29","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/JVI.70.7.4805-4810.1996","article-title":"Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli","volume":"70","author":"Chartier","year":"1996","journal-title":"J Virol"},{"key":"10.1038\/mtm.2016.30_bib30","first-page":"389","article-title":"Construction of first-generation adenoviral vectors","volume":"69","author":"Ng","year":"2002","journal-title":"Methods Mol Med"},{"key":"10.1038\/mtm.2016.30_bib31","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2007.135","article-title":"A protocol for rapid generation of recombinant adenoviruses using the AdEasy system","volume":"2","author":"Luo","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1038\/mtm.2016.30_bib32","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1089\/hum.1998.9.17-2577","article-title":"Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method","volume":"9","author":"Mizuguchi","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib33","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/nprot.2010.134","article-title":"An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector","volume":"5","author":"Zhou","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1038\/mtm.2016.30_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/biot.201400390","article-title":"Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials","volume":"10","author":"Kallel","year":"2015","journal-title":"Biotechnol J"},{"issue":"suppl. 1","key":"10.1038\/mtm.2016.30_bib35","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1002\/jgm.503","article-title":"Development and optimization of an adenovirus production process","volume":"6","author":"Kamen","year":"2004","journal-title":"J Gene Med"},{"key":"10.1038\/mtm.2016.30_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/hum.2005.16.281","article-title":"Good manufacturing practice production of adenoviral vectors for clinical trials","volume":"16","author":"Lusky","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib37","series-title":"WHO Global Tuberculosis Report 2015","author":"WHO","year":"2015"},{"key":"10.1038\/mtm.2016.30_bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.immunol.021908.132703","article-title":"Cell-mediated immune responses in tuberculosis","volume":"27","author":"Cooper","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/mtm.2016.30_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro3230","article-title":"In search of a new paradigm for protective immunity to TB","volume":"12","author":"Nunes-Alves","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1038\/mtm.2016.30_bib40","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.4049\/jimmunol.181.7.4955","article-title":"Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice","volume":"181","author":"Forbes","year":"2008","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2016.30_bib41","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","article-title":"Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis","volume":"173","author":"Wang","year":"2004","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2016.30_bib42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mi.2012.19","article-title":"Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells","volume":"5","author":"Horvath","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1038\/mtm.2016.30_bib43","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1128\/IAI.00517-06","article-title":"Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis","volume":"74","author":"Santosuosso","year":"2006","journal-title":"Infect Immun"},{"key":"10.1038\/mtm.2016.30_bib44","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4049\/jimmunol.178.4.2387","article-title":"Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization","volume":"178","author":"Santosuosso","year":"2007","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2016.30_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fimmu.2014.00321","article-title":"The immunodominant T-cell epitopes of the mycolyl-transferases of the antigen 85 complex of M. tuberculosis","volume":"5","author":"Huygen","year":"2014","journal-title":"Front Immunol"},{"key":"10.1038\/mtm.2016.30_bib46","doi-asserted-by":"crossref","first-page":"e0135009","DOI":"10.1371\/journal.pone.0135009","article-title":"AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-primed non-human primates","volume":"10","author":"Jeyanathan","year":"2015","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib47","doi-asserted-by":"crossref","first-page":"e5856","DOI":"10.1371\/journal.pone.0005856","article-title":"Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis","volume":"4","author":"Xing","year":"2009","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib48","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jgm.1487","article-title":"Respiratory mucosal immunization with adenovirus gene transfer vector induces helper CD4 T cell-independent protective immunity","volume":"12","author":"Mu","year":"2010","journal-title":"J Gene Med"},{"key":"10.1038\/mtm.2016.30_bib49","doi-asserted-by":"crossref","first-page":"e0142270","DOI":"10.1371\/journal.pone.0142270","article-title":"Protection induced by simultaneous subcutaneous and endobronchial vaccination with BCG\/BCG and BCG\/adenovirus expressing antigen 85A against Mycobacterium bovis in cattle","volume":"10","author":"Dean","year":"2015","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib50","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.30_bib51","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy","volume":"27","author":"Dudareva","year":"2009","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib52","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2016.30_bib53","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/JCM.01249-06","article-title":"Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa","volume":"44","author":"Thorner","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1038\/mtm.2016.30_bib54","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.00004-07","article-title":"Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon","volume":"75","author":"Radosevic","year":"2007","journal-title":"Infect Immun"},{"key":"10.1038\/mtm.2016.30_bib55","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.4049\/jimmunol.1400676","article-title":"Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge","volume":"193","author":"Darrah","year":"2014","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2016.30_bib56","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.4161\/hv.29108","article-title":"A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402\/Ad35 vaccine: evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs","volume":"10","author":"Hokey","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1038\/mtm.2016.30_bib57","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells\/mm(3)","volume":"33","author":"Churchyard","year":"2015","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib58","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib59","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1038\/mtm.2016.30_bib60","doi-asserted-by":"crossref","first-page":"e0141687","DOI":"10.1371\/journal.pone.0141687","article-title":"A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib61","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2015.03.070","article-title":"A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants","volume":"33","author":"Tameris","year":"2015","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib62","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.vaccine.2013.11.055","article-title":"Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression","volume":"32","author":"Johnson","year":"2014","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib63","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.4049\/jimmunol.1103717","article-title":"Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity","volume":"188","author":"Johnson","year":"2012","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2016.30_bib64","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/mi.2012.103","article-title":"Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity","volume":"6","author":"Jeyanathan","year":"2013","journal-title":"Mucosal Immunol"},{"key":"10.1038\/mtm.2016.30_bib65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mtm.2016.30_bib66","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1126\/science.1233665","article-title":"Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses","volume":"339","author":"Teles","year":"2013","journal-title":"Science"},{"key":"10.1038\/mtm.2016.30_bib67","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/10430340460745838","article-title":"Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors","volume":"15","author":"Roy","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.30_bib68","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib69","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/mi.2015.29","article-title":"Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection","volume":"8","author":"Jeyanathan","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1038\/mtm.2016.30_bib70","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.30_bib71","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(06)68076-8","article-title":"Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice","volume":"367","author":"Hoelscher","year":"2006","journal-title":"Lancet"},{"key":"10.1038\/mtm.2016.30_bib72","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1038\/mtm.2016.30_bib74","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1016\/j.vaccine.2007.07.035","article-title":"Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein","volume":"25","author":"Roy","year":"2007","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib75","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.30_bib76","doi-asserted-by":"crossref","first-page":"e13162","DOI":"10.1371\/journal.pone.0013162","article-title":"Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses","volume":"5","author":"Price","year":"2010","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib77","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1128\/JVI.00823-14","article-title":"Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice","volume":"88","author":"Kim","year":"2014","journal-title":"J Virol"},{"key":"10.1038\/mtm.2016.30_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ni.2761","article-title":"Universal influenza virus vaccines: need for clinical trials","volume":"15","author":"Krammer","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1038\/mtm.2016.30_bib79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nri2674","article-title":"The immune response during acute HIV-1 infection: clues for vaccine development","volume":"10","author":"McMichael","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mtm.2016.30_bib80","doi-asserted-by":"crossref","first-page":"e67574","DOI":"10.1371\/journal.pone.0067574","article-title":"Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV","volume":"8","author":"Weaver","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib81","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0966-842X(00)01816-3","article-title":"The chimpanzee and other non-human-primate models in HIV-1 vaccine research","volume":"8","author":"Nath","year":"2000","journal-title":"Trends Microbiol"},{"key":"10.1038\/mtm.2016.30_bib82","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"10.1038\/mtm.2016.30_bib83","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1086\/587993","article-title":"Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag\/pol\/nef vaccine in healthy adults","volume":"46","author":"Priddy","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1038\/mtm.2016.30_bib84","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/mtm.2016.30_bib85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1038\/mtm.2016.30_bib86","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)","volume":"206","author":"Duerr","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1038\/mtm.2016.30_bib87","doi-asserted-by":"crossref","first-page":"e106004","DOI":"10.1371\/journal.pone.0106004","article-title":"Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques","volume":"9","author":"Qureshi","year":"2014","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.30_bib88","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.30_bib89","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1016\/j.vaccine.2015.10.111","article-title":"Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen","volume":"33","author":"Herath","year":"2015","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.30_bib90","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J Clin Invest"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116301735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116301735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T04:36:26Z","timestamp":1600490186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050116301735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":90,"alternative-id":["S2329050116301735"],"URL":"https:\/\/doi.org\/10.1038\/mtm.2016.30","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"article-number":"16030"}}